<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="ago, just three drugs were available for the treatment of" exact="viral" post="infections, but now more than forty have been approved."/>
 <result pre="nucleoside analogues, in particular acyclovir, could inhibit DNA replication of" exact="herpes" post="simplex virus (HSV) at concentrations far below those that"/>
 <result pre="thymidine kinase — was unexpected, but the potential for exploiting" exact="viral" post="enzymes to develop potent and specific antiviral drugs was"/>
 <result pre="in the early 1980s in the face of a new" exact="viral" post="pathogen: human immunodeficiency virus (HIV, then called LAV-1/HTLV-III), which"/>
 <result pre="1980s in the face of a new viral pathogen: human" exact="immunodeficiency" post="virus (HIV, then called LAV-1/HTLV-III), which was identified as"/>
 <result pre="analogues selected by Wellcome Laboratories and evaluated by the National" exact="Cancer" post="Institute. Again, the selectivity of the inhibitory activity of"/>
 <result pre="the selectivity of the inhibitory activity of AZT for a" exact="viral" post="enzyme — HIV reverse transcriptase — compared with enzymes"/>
 <result pre="drug design — then facilitated a new approach to targeting" exact="viral" post="enzymes, guided by rational design. Efforts to elucidate the"/>
 <result pre="revealed that a virally encoded aspartyl protease was crucial in" exact="viral" post="replication. Specific design of protease inhibitors based on the"/>
 <result pre="began the era of highly active antiretroviral therapy (HAART), transforming" exact="HIV infection" post="from a death sentence to a chronically manageable disease."/>
 <result pre="the era of highly active antiretroviral therapy (HAART), transforming HIV" exact="infection" post="from a death sentence to a chronically manageable disease."/>
 <result pre="the development of similar approaches for the treatment of other" exact="viral" post="infections, in particular hepatitis C virus (HCV). Although HCV"/>
 <result pre="approaches for the treatment of other viral infections, in particular" exact="hepatitis" post="C virus (HCV). Although HCV is fundamentally different to"/>
 <result pre="is fundamentally different to HIV, several classes of drugs targeting" exact="viral" post="enzymes — in this case HCV RNA replicase and"/>
 <result pre="and implementing drug therapies for several other virus infections, including" exact="hepatitis" post="B virus and influenza virus. Severe acute respiratory syndrome"/>
 <result pre="other virus infections, including hepatitis B virus and influenza virus." exact="Severe" post="acute respiratory syndrome (SARS) virus and other respiratory virus"/>
 <result pre="virus infections, including hepatitis B virus and influenza virus. Severe" exact="acute" post="respiratory syndrome (SARS) virus and other respiratory virus infections"/>
 <result pre="infections, including hepatitis B virus and influenza virus. Severe acute" exact="respiratory" post="syndrome (SARS) virus and other respiratory virus infections that"/>
 <result pre="including hepatitis B virus and influenza virus. Severe acute respiratory" exact="syndrome" post="(SARS) virus and other respiratory virus infections that may"/>
 <result pre="influenza virus. Severe acute respiratory syndrome (SARS) virus and other" exact="respiratory" post="virus infections that may (re)-emerge at any time, and"/>
 <result pre="Severe acute respiratory syndrome (SARS) virus and other respiratory virus" exact="infections" post="that may (re)-emerge at any time, and haemorrhagic fever"/>
 <result pre="any time, and haemorrhagic fever virus (such as Ebola) and" exact="encephalitis" post="virus (such as West Nile) infections, also merit serious"/>
 <result pre="serious attention. The ongoing need to combat existing and emerging" exact="viral" post="infections calls for continued collaboration between medicinal chemists and"/>
 <result pre="attention. The ongoing need to combat existing and emerging viral" exact="infections" post="calls for continued collaboration between medicinal chemists and biomedical"/>
</results>
